BioPharma Credit PLC
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in London, the United Kingdom.
BioPharma Credit PLC (BOPCF) - Total Liabilities
Latest total liabilities as of June 2025: $7.49 Million USD
Based on the latest financial reports, BioPharma Credit PLC (BOPCF) has total liabilities worth $7.49 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BioPharma Credit PLC - Total Liabilities Trend (2017–2024)
This chart illustrates how BioPharma Credit PLC's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BioPharma Credit PLC Competitors by Total Liabilities
The table below lists competitors of BioPharma Credit PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Raven Industries Inc
F:RV1
|
Germany | €5.93 Billion |
|
Bajaj Housing Finance
NSE:BAJAJHFL
|
India | ₹947.96 Billion |
|
Elders Ltd
AU:ELD
|
Australia | AU$1.56 Billion |
|
Cadeler As
OL:CADLR
|
Norway | Nkr1.61 Billion |
|
UNITIL Corporation
NYSE:UTL
|
USA | $1.35 Billion |
|
Bright Smart Securities & Commodities Group Limited
F:0BX
|
Germany | €8.35 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down BioPharma Credit PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioPharma Credit PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioPharma Credit PLC (2017–2024)
The table below shows the annual total liabilities of BioPharma Credit PLC from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $17.94 Million | +13.03% |
| 2023-12-31 | $15.87 Million | -39.66% |
| 2022-12-31 | $26.30 Million | +281.17% |
| 2021-12-31 | $6.90 Million | -26.54% |
| 2020-12-31 | $9.39 Million | -62.78% |
| 2019-12-31 | $25.23 Million | +90.44% |
| 2018-12-31 | $13.25 Million | +354.42% |
| 2017-12-31 | $2.92 Million | -- |